Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer

被引：5
作者：
Pronzato, Paolo [1 ]
机构：
[1] IST, Oncol Med, Genoa, Italy
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 16期
关键词：
endocrine resistance; everolimus; HER2; negative; HR positive; metastatic breast cancer; mTOR inhibition; PROGRESSION-FREE SURVIVAL; PLUS EXEMESTANE; NETWORK METAANALYSIS; POSTMENOPAUSAL WOMEN; ENDOCRINE THERAPY; AMERICAN SOCIETY; MAMMALIAN TARGET; BOLERO-2; TRIAL; EFFICACY; CHEMOTHERAPY;
D O I：
10.2217/fon-2017-0098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Metastatic breast cancer (mBC) is a leading cause of mortality for women around the world. The response to hormonotherapy of the patients with HER2-negative/HR-positive mBC is usually limited, and many strategies are in place to contrast the hormonotherapy resistance. Since efficacy and effectiveness of everolimus have been established by many trials, this review is aimed to give a structured synthesis to define the everolimus clinical role among the treatment options for mBC. Key aspects of everolimus dosing and safety profile, drawn up by relevant findings, are included, as well as the role of biomarkers to identify subgroups of mBC patients who may best benefit from everolimus treatment.
引用
收藏
页码：1371 / 1384
页数：14
相关论文
共 63 条
[51]   Everolimus in the Treatment of Metastatic Breast Cancer [J].
Royce, Melanie E. ;
Osman, Diaa .
BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2015, 9 :73-79
[52]   Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 [J].
Rugo, H. S. ;
Pritchard, K. I. ;
Gnant, M. ;
Noguchi, S. ;
Piccart, M. ;
Hortobagyi, G. ;
Baselga, J. ;
Perez, A. ;
Geberth, M. ;
Csoszi, T. ;
Chouinard, E. ;
Srimuninnimit, V. ;
Puttawibul, P. ;
Eakle, J. ;
Feng, W. ;
Bauly, H. ;
El-Hashimy, M. ;
Taran, T. ;
Burris, H. A., III .
ANNALS OF ONCOLOGY, 2014, 25 (04) :808-815
[53]   Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary [J].
Rugo, Hope S. ;
Rumble, R. Bryan ;
Burstein, Harold J. .
JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (06) :583-U246
[54]   Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer [J].
Rugo, Hope S. .
CLINICAL BREAST CANCER, 2016, 16 (01) :18-22
[55]   Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials [J].
Saad, Everardo D. ;
Katz, Artur ;
Buyse, Marc .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1958-1962
[56]   Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors [J].
Tabernero, Josep ;
Rojo, Federico ;
Calvo, Emiliano ;
Burris, Howard ;
Judson, Ian ;
Hazell, Katharine ;
Martinelli, Erika ;
Cajal, Santiago Ramon Y. ;
Jones, Suzanne ;
Vidal, Laura ;
Shand, Nicholas ;
Macarulla, Teresa ;
Ramos, Francisco Javier ;
Dimitrijevic, Sasa ;
Zoellner, Ulrike ;
Tang, Pui ;
Stumm, Michael ;
Lane, Heidi A. ;
Lebwohl, David ;
Baselga, Jose .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1603-1610
[57]  
Tanaka Chiaki, 2008, J Clin Oncol, V26, P1596, DOI 10.1200/JCO.2007.14.1127
[58]   Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer [J].
Treilleux, I. ;
Arnedos, M. ;
Cropet, C. ;
Wang, Q. ;
Ferrero, J. -M. ;
Abadie-Lacourtoisie, S. ;
Levy, C. ;
Legouffe, E. ;
Lortholary, A. ;
Pujade-Lauraine, E. ;
Bourcier, A. -V. ;
Eymard, J. -C. ;
Spaeth, D. ;
Bachelot, T. .
ANNALS OF ONCOLOGY, 2015, 26 (01) :120-125
[59]   Clinical development of mTOR inhibitors in breast cancer [J].
Vicier, Cecile ;
Dieci, Maria Vittoria ;
Arnedos, Monica ;
Delaloge, Suzette ;
Viens, Patrice ;
Andre, Fabrice .
BREAST CANCER RESEARCH, 2014, 16 (01)
[60]   S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation [J].
Yamnik, Rachel L. ;
Digilova, Alla ;
Davis, Daphne C. ;
Brodt, Z. Nilly ;
Murphy, Christopher J. ;
Holz, Marina K. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (10) :6361-6369
1234567